All In Biotech

Drug Trial Radar · NCT06434597

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

A Multicenter, Open, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of SPH5030 Tablets in Subjects With Her2-positive/Mutated Biliary Tract OR Colorectal Cancer.

Last checked: Nov 19, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 17, 2024

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
May 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer.

Conditions

  • Biliary Tract or Colorectal Cancer With Her2-positive/Mutated

Interventions

  • SPH5030Drug

    SPH5030:Oral, QD, 600mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Approximately 2 years

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital,Capital Medical University

    Beijing, China · Recruiting

  • Chinese PLA General hospital

    Beijing, China · Recruiting

  • Peking Union Medical College Hospital

    Beijing, China · Recruiting

  • The Second Affiliatedf Hospital of AFMU

    Beijing, China · Recruiting

  • XiangYa Hospital CentralSouth University

    Changsha, China · Recruiting

  • Changzhi People's Hospital

    Changzhi, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, China · Recruiting

  • General Hospital of Fuzhou

    Fuzhou, China · Recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, China · Recruiting

  • Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine

    Hangzhou, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, China · Recruiting

  • Anhui Provincial Cancer Hospital

    Hefei, China · Recruiting

  • Hengshui People's Hospital

    Hengshui, China · Recruiting

  • Yunnan Cancer Hospital

    Kunming, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Recruiting

  • Shanghai General Hospital

    Shanghai, China · Recruiting

  • The Third Affiliated Hospital of Air Force Medical University

    Shanghai, China · Recruiting

  • Zhongshan Hospital

    Shanghai, China · Recruiting

  • Shantou University Medical College Cancer Hospital

    Shantou, China · Recruiting

  • Liaoning Cancer Hospital

    Shenyang, China · Recruiting

  • Shanxi Cancer Hospital

    Taiyuan, China · Recruiting

  • Tianjin Medical University Cancer institute & Hospital

    Tianjin, China · Recruiting

  • Hubei Cancer Hospital

    Wuhan, China · Recruiting

  • Affiliated Hospital of Jiangnan University

    Wuxi, China · Recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, China · Recruiting

  • Xiangyang Central Hospital

    Xiangyang, China · Recruiting

  • Yantai Yuhuangding Hospital

    Yantai, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.